Dr. Harriet Feilotter
Dr. Harriet Feilotter
Contact
Dr. Harriet Feilotter
Ontario Molecular Pathology Research Network Director and Lead, Clinical Implementation

hf4@queensu.ca

Ontario Molecular Pathology Research Network Director and Lead, Clinical Implementation

Dr. Harriet Feilotter’s research focuses on the implementation of biomarkers to be used in the screening, diagnosis or treatment of human diseases, including cancer.

Using her dual role as a researcher in Pathology and Molecular Medicine, and service chief of laboratory genetics at the Kingston Health Sciences Center, her research is geared towards clinical applications of targeted biomarkers.

Her research includes the study of DNA, RNA and protein biomarkers in a variety of diseases including breast, lung, melanoma, bladder and colon cancers. The Feilotter Lab makes use of multiple platforms, including massively parallel sequencing, to generate and validate targeted biomarker data. Her primary focus is in developing and standardizing pathways for the effective implementation of robustly evaluated biomarkers in the clinical setting, including the assessment of quality metrics.  To that end, she engages in community ring studies to assess methodology for evaluation of analytic parameters for targeted molecular assays. Due to the networked nature of the work, she also has an interest and focus in informatics, including the proper handling, storage and sharing of biomarker data, the preprocessing pipelines required to ensure high quality data, the analytic pipelines needed to deliver an effective clinical tool and the ability to federate multiple types of data into formats suitable for sharing, querying and storing.

Experience & Education
  • Genetics Consultant, St. Michael’s Hospital, Toronto
  • Acting Clinical Chief, Genetics, Laboratory Medicine, Eastern Health, Newfoundland
  • Assistant/Associate Professor, Dept. of Pathology and Molecular Medicine, Queen’s University
  • CCMG Fellow, Kingston General Hospital
  • Post doctoral research fellow, Cold Spring Harbor Laboratory
  • PhD research, Dept. of Microbiology, University of Oxford
  • PhD candidate, Dept. of Biology, Queen’s University
  • M.Sc. candidate, Dept. of Biology, Queen’s University
Current Affiliations
  • Lead, Clinical Implementation, OICR
  • Senior Scientist, Canadian Clinical Trials Group
  • Chief Scientific Officer and member, Indoc Research
  • Professor, Dept. of Pathology and Molecular Medicine, Queen’s University
  • Service Chief, Division of Laboratory Genetics, Kingston Health Sciences Center
  • Director, Molecular Genetics Laboratory, Kingston Health Sciences Center
  • Associate Member, Cancer Research Institute, Queen’s University
  • Chair, Molecular Oncology Advisory Committee, Cancer Care Ontario
Select Publications

See Dr. Feilotter’s recent publications on PubMed.

Research Areas
Biology Early Detection and Diagnosis
Disease Areas
Breast
Awards
  • Ontario Brain Institute, Top Achievement, 2017
  • Women in Cancer Research International Women’s Day write-up, 2017
  • The Pathologist, Cover Story, 2017
  • Canadians for Health Research, Researcher of the Month, 2016
  • Hamerton Service Award, Canadian College of Medical Geneticists, 2021
Opportunities to Collaborate

To collaborate with Dr. Feilotter, please contact her directly.

Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.

In the News
Ontario experts chart vision to advance machine learning for cancer care
Ontario experts chart vision to advance machine learning for cancer care
May 20, 2021
Funding from Ontario Institute for Cancer Research to help move research from experiment to impact
Funding from Ontario Institute for Cancer Research to help move research from experiment to impact
Aug 11, 2022
Low-cost molecular test targets more efficient brain cancer diagnosis
Low-cost molecular test targets more efficient brain cancer diagnosis
Jan 12, 2023
OPINION: A pathway to faster access to life-saving cancer innovations
OPINION: A pathway to faster access to life-saving cancer innovations
Aug 01, 2024